Efficacy and Safety of IQP-VV-102 in Weight Management

InQpharm Group120 enrolled

Overview

Subjects are randomized to either IQP-VV-102 or a matching placebo. Over 12 weeks, the subjects' body weight, body fat and safety parameters are monitored

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

120

Conditions

Obesity Overweight

Interventions

IQP-VV-102DIETARY_SUPPLEMENT

PlaceboOTHER

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18 to 60 years * 25 kg/m2 ≤ BMI ≤ 35 kg/m2 * Written informed consent Exclusion Criteria: * Known sensitivity to sources of the active ingredients and excipients * Pregnancy or nursing * Inability to comply with study requirements, e.g. due to language difficulties * Participation in another study during the last 30 days of the screening visit

Locations (1)

Barbara Grube

Berlin, State of Berlin, Germany

Outcomes

Primary Outcomes

Change in Body Weight at End of Study Compared to Baseline

Change in body weight at the end of study compared to baseline

Time frame: 12 weeks

Secondary Outcomes

Change in Waist Circumference (in cm) at End of Study From Baseline

Difference in waist circumference (in cm) at end of study from baseline

Time frame: 12 weeks

Change in Mean Body Fat at End of Study From Baseline

Measured in kg using calibrated weighing scales

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.